Heartflow, Inc. (HTFL) shareholders
HTFLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30437% above fair value
$48.46−11.46 (-19.13%)
Close on Nov 13, 2026Market cap $4.21BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.0%
75M of 87M shares
Institutional holders
193
51 new, 24 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
1 buys · 40 sales
Net sold $142.63M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (14.00%), Wellington Investment Advisors Holdings LLP (14.00%) and 1 more | 11,921,247 | 14.00% | 13G (passive) amendment | Feb 27, 2026 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (10.70%), Wellington Investment Advisors Holdings LLP (10.70%) and 1 more | 9,232,829 | 10.70% | 13G (passive) amendment | Jul 31, 2026 |
| BCLS Fund III Investments, LP | 8,448,158 | 9.80% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (9.10%), Wellington Group Holdings LLP (9.10%) and 1 more | 7,864,226 | 8.90% | 13G (passive) amendment | Jun 30, 2026 |
| Hayfin Management Holdings Limited | 5,283,264 | 6.20% | 13G (passive) | Sep 30, 2025 |
| BlackRock, Inc. | 4,934,928 | 5.70% | 13G (passive) | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.70%) | 4,730,234 | 5.70% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HTFL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,448,158 | 9.72% | $247.87M | −2,000,000 | 14.74% |
| Wellington Management Group Llp | 7,864,226 | 9.04% | $230.74M | −4,118,057 | 0.04% |
| BlackRock, Inc. | 5,197,747 | 5.98% | $152.50M | +3,735,163 | 0.00% |
| FMR LLC | 4,820,944 | 5.54% | $141.45M | −576,858 | 0.01% |
| Vanguard Portfolio Management LLC | 3,584,428 | 4.12% | $105.17M | +1,538,490 | 0.00% |
| Bamco Inc /Ny/ | 3,225,133 | 3.71% | $94.63M | −602,398 | 0.14% |
| Vanguard Capital Management LLC | 2,753,206 | 3.17% | $80.78M | +859,711 | 0.00% |
| Jupiter Topco LLC | 2,419,336 | 2.78% | $70.98M | New | 0.03% |
| Invesco Ltd. | 2,298,718 | 2.64% | $67.44M | +385,628 | 0.01% |
| Alliancebernstein L.P. | 1,924,268 | 2.21% | $46.82M | +699,942 | 0.02% |
| Point72 Asset Management, L.P. | 1,721,279 | 1.98% | $50.50M | +1,182,928 | 0.06% |
| Summit Partners Public Asset Management, LLC | 1,694,651 | 1.95% | $49.72M | +802,558 | 0.87% |
| State Street Corp | 1,465,895 | 1.69% | $43.27M | +1,015,345 | 0.00% |
| UBS Asset Management Americas Inc | 1,465,650 | 1.69% | $43.00M | +50,822 | 0.01% |
| Geode Capital Management, LLC | 1,360,391 | 1.56% | $39.92M | +818,732 | 0.00% |
| Nuveen, LLC | 1,353,168 | 1.56% | $39.70M | +1,329,929 | 0.01% |
| Morgan Stanley | 1,054,889 | 1.21% | $30.95M | +202,957 | 0.00% |
| UBS Group AG | 975,510 | 1.12% | $28.62M | +546,426 | 0.00% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 931,160 | 1.07% | $27.32M | New | 0.03% |
| Millennium Management LLC | 922,893 | 1.06% | $27.08M | −170,524 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 193 | 75M | 86.0% | 51 / 91 | 37 / 24 | 24M | 12M |
| Q1 2026 | 169 | 65M | 74.8% | 75 / 50 | 26 / 15 | 24M | 10M |
| Q4 2025 | 112 | 52M | 60.2% | 49 / 37 | 13 / 24 | 12M | 4M |
| Q3 2025 | 89 | 45M | 51.5% | 89 / 0 | 0 / 0 | 45M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
218 funds held HTFL in Q2 2026, 27% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HTFL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 5,795,579 | 6.67% | $146.22M | 0.38% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,467,177 | 2.84% | $72.39M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,077,580 | 2.39% | $60.96M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,781,440 | 2.05% | $52.27M | 0.03% | Jun 30, 2026 |
| Baron Discovery Fund | 1,604,894 | 1.85% | $47.09M | 2.57% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 1,127,593 | 1.30% | $33.08M | 0.05% | Jun 30, 2026 |
| Invesco Discovery Fund | 1,116,228 | 1.28% | $34.58M | 0.44% | May 31, 2026 |
| Select Health Care Portfolio | 1,000,000 | 1.15% | $30.98M | 0.54% | May 31, 2026 |
| Select Medical Technology and Devices Portfolio | 950,000 | 1.09% | $29.43M | 0.99% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 879,047 | 1.01% | $22.18M | 0.07% | Jul 31, 2026 |
| AB Small Cap Growth Portfolio | 830,401 | 0.95% | $24.36M | 0.78% | Jun 30, 2026 |
| Janus Henderson Venture Fund | 781,479 | 0.90% | $22.93M | 0.63% | Jun 30, 2026 |
| Franklin Dynatech Fund | 750,000 | 0.86% | $22.01M | 0.07% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 742,105 | 0.85% | $21.77M | 0.14% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 618,055 | 0.71% | $18.13M | 0.31% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John C.M. Farquhar | Chief Executive Officer, Director | 251,983 | 0.29% | Nov 10, 2026 |
| Campbell Rogers | Chief Medical Officer | 216,723 | 0.25% | Nov 10, 2026 |
| Vikram Verghese | Chief Financial Officer | 149,587 | 0.17% | Nov 10, 2026 |
| Marie L. Jones | Chief Accounting Officer | 32,403 | 0.04% | Nov 10, 2026 |
| Jeffrey C. Lightcap | Director | 6,991,237 | 8.04% | Jul 28, 2026 |
| Timothy C. Barabe | Director | 188,231 | 0.22% | Jul 24, 2026 |
| William C. Weldon | Director | 243,931 | 0.28% | Jul 10, 2026 |
| Casey M. Tansey | Director | 3,187,509 | 3.67% | Jun 18, 2026 |
| Wayne Joseph Riley | Director | – | – | Jun 18, 2026 |
| Julie A. Cullivan | Director | 27,291 | 0.03% | Jun 18, 2026 |
| Partners Management LP HealthCor | Director | 0 | – | Mar 26, 2026 |
| Nicholas Downing | Director | – | – | Aug 7, 2025 |
| Bain Capital Life Sciences Fund III, L.P. | 10% owner | 12,448,158 | 14.32% | Apr 30, 2026 |
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | 8,448,158 | 9.72% | Apr 30, 2026 |
| BCLS Fund III Investments, LP | 10% owner | – | – | Apr 30, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | 10,448,158 | 12.02% | Apr 30, 2026 |
| BCLS Fund III Investments GP, LLC | 10% owner | – | – | Apr 30, 2026 |
| HealthCor Partners Fund II, L.P. | 10% owner | – | – | Aug 22, 2025 |
| Partners Fund LP HealthCor | 10% owner | – | – | Aug 22, 2025 |
| Partners LP HealthCor | 10% owner | – | – | Aug 22, 2025 |
| HealthCor Partners GP, LLC | 10% owner | 6,697,556 | 7.70% | Aug 22, 2025 |
| Hcpciv 1, Llc | 10% owner | – | – | Aug 22, 2025 |
| HealthCor Partners II, L.P. | 10% owner | – | – | Aug 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John C.M. Farquhar Chief Executive Officer, Director | Nov 10, 2026 | Sale(10b5-1 plan) | −38,900 | $55.74 | $2.17M | 251,983 |
| John C.M. Farquhar Chief Executive Officer, Director | Nov 10, 2026 | Option exercise | +15,620 | $2.22 | $34.68K | 290,883 |
| Vikram Verghese Chief Financial Officer | Nov 9, 2026 | Sale(10b5-1 plan) | −3,587 | $53.15 | $190.65K | 149,587 |
| John C.M. Farquhar Chief Executive Officer, Director | Nov 6, 2026 | Tax withholding | −7,751 | $52.40 | $406.15K | 275,263 |
| Vikram Verghese Chief Financial Officer | Nov 6, 2026 | Tax withholding | −2,009 | $52.40 | $105.27K | 153,174 |
| Campbell Rogers Chief Medical Officer | Nov 6, 2026 | Tax withholding | −2,270 | $52.40 | $118.95K | 71,183 |
| Marie L. Jones Chief Accounting Officer | Nov 6, 2026 | Tax withholding | −568 | $52.40 | $29.76K | 32,403 |
| Campbell Rogers Chief Medical Officer | Oct 22, 2026 | Sale(10b5-1 plan) | −23,933 | $55.01 | $1.32M | 73,453 |
| Campbell Rogers Chief Medical Officer | Oct 22, 2026 | Option exercise | +5,101 | $2.22 | $11.32K | 97,386 |
| Campbell Rogers Chief Medical Officer | Oct 22, 2026 | Option exercise | +12,329 | $8.33 | $102.70K | 92,285 |
| John C.M. Farquhar Chief Executive Officer, Director | Oct 12, 2026 | Sale(10b5-1 plan) | −38,900 | $49.57 | $1.93M | 283,014 |
| Campbell Rogers Chief Medical Officer | Sep 18, 2026 | Option exercise | +12,329 | $8.33 | $102.70K | 98,788 |
| Campbell Rogers Chief Medical Officer | Sep 18, 2026 | Option exercise | +850 | $2.22 | $1.89K | 99,638 |
| Campbell Rogers Chief Medical Officer | Sep 18, 2026 | Sale(10b5-1 plan) | −19,682 | $50.15 | $987.05K | 79,956 |
| Vikram Verghese Chief Financial Officer | Sep 18, 2026 | Sale(10b5-1 plan) | −16,766 | $50.75 | $850.87K | 155,183 |
| Vikram Verghese Chief Financial Officer | Sep 17, 2026 | Sale(10b5-1 plan) | −7,579 | $50.11 | $379.78K | 171,949 |
| Vikram Verghese Chief Financial Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −668 | $50.01 | $33.41K | 179,528 |
| Vikram Verghese Chief Financial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −4,593 | $50.24 | $230.75K | 180,196 |
| Vikram Verghese Chief Financial Officer | Sep 11, 2026 | Sale(10b5-1 plan) | −29,714 | $50.06 | $1.49M | 184,789 |
| John C.M. Farquhar Chief Executive Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −3,890 | $50.00 | $194.50K | 321,914 |
| John C.M. Farquhar Chief Executive Officer, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −35,010 | $46.42 | $1.63M | 325,804 |
| Marie L. Jones Chief Accounting Officer | Sep 8, 2026 | Award | +795 | $19.70 | $15.66K | 32,971 |
| Vikram Verghese Chief Financial Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −6,640 | $50.03 | $332.20K | 214,503 |
| Vikram Verghese Chief Financial Officer | Sep 3, 2026 | Sale(10b5-1 plan) | −27,540 | $49.69 | $1.37M | 221,143 |
| Vikram Verghese Chief Financial Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −5,876 | $50.60 | $297.33K | 248,683 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −27,230 | $50.00 | $1.36M | 360,814 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −32,676 | $45.00 | $1.47M | 388,044 |
| Campbell Rogers Chief Medical Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −9,219 | $41.23 | $380.10K | 86,459 |
| Campbell Rogers Chief Medical Officer | Aug 17, 2026 | Option exercise | +9,219 | $19.00 | $175.16K | 95,678 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 14, 2026 | Sale(10b5-1 plan) | −15,560 | $39.06 | $607.77K | 420,720 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −22,562 | $28.31 | $638.73K | 436,280 |
| Vikram Verghese Chief Financial Officer | Aug 7, 2026 | Tax withholding | −473 | $28.82 | $13.63K | 254,559 |
| Campbell Rogers Chief Medical Officer | Aug 7, 2026 | Tax withholding | −637 | $28.82 | $18.36K | 86,459 |
| Marie L. Jones Chief Accounting Officer | Aug 7, 2026 | Tax withholding | −82 | $28.82 | $2.36K | 32,176 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 7, 2026 | Tax withholding | −1,904 | $28.82 | $54.87K | 458,842 |
| Vikram Verghese Chief Financial Officer | Aug 6, 2026 | Tax withholding | −1,537 | $27.19 | $41.79K | 255,032 |
| Campbell Rogers Chief Medical Officer | Aug 6, 2026 | Tax withholding | −1,635 | $27.19 | $44.46K | 87,096 |
| Marie L. Jones Chief Accounting Officer | Aug 6, 2026 | Tax withholding | −486 | $27.19 | $13.21K | 32,258 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 6, 2026 | Tax withholding | −5,847 | $27.19 | $158.98K | 460,746 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 30, 2026 | Option exercise | +18,694 | $2.22 | $41.50K | 456,856 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 30, 2026 | Option exercise | +2,789 | $8.33 | $23.23K | 438,162 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 30, 2026 | Option exercise | +9,737 | $9.58 | $93.28K | 466,593 |
| Vikram Verghese Chief Financial Officer | Jul 27, 2026 | Option exercise | +22,522 | $2.22 | $50.00K | 255,898 |
| Jeffrey C. Lightcap Director | Jul 24, 2026 | Option exercise | +47,420 | $19.00 | $900.98K | 293,681 |
| Timothy C. Barabe Director | Jul 22, 2026 | Option exercise | +3,710 | $19.00 | $70.49K | 188,231 |
| Vikram Verghese Chief Financial Officer | Jul 21, 2026 | Option exercise | +22,522 | $2.22 | $50.00K | 233,376 |
| Timothy C. Barabe Director | Jul 17, 2026 | Option exercise | +5,000 | $19.00 | $95.00K | 184,521 |
| Campbell Rogers Chief Medical Officer | Jul 15, 2026 | Option exercise | +9,219 | $19.00 | $175.16K | 97,950 |
| Campbell Rogers Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −9,219 | $25.72 | $237.11K | 88,731 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −22,562 | $27.75 | $626.10K | 435,373 |
| William C. Weldon Director | Jul 8, 2026 | Option exercise | +17,123 | $8.33 | $142.63K | 243,931 |
| William C. Weldon Director | Jul 8, 2026 | Option exercise | +17,123 | $8.33 | $142.63K | 226,808 |
| William C. Weldon Director | Jul 8, 2026 | Option exercise | +17,123 | $8.33 | $142.63K | 209,685 |
| John C.M. Farquhar Chief Executive Officer, Director | Jun 24, 2026 | Sale(10b5-1 plan) | −38,900 | $35.00 | $1.36M | 457,935 |
| Campbell Rogers Chief Medical Officer | Jun 15, 2026 | Option exercise | +10,000 | $2.22 | $22.20K | 88,731 |
| John C.M. Farquhar Chief Executive Officer, Director | Jun 10, 2026 | Sale(10b5-1 plan) | −22,562 | $28.50 | $643.02K | 496,835 |
| Campbell Rogers Chief Medical Officer | May 18, 2026 | Sale(10b5-1 plan) | −9,219 | $28.34 | $261.27K | 78,731 |
| Campbell Rogers Chief Medical Officer | May 18, 2026 | Option exercise | +9,219 | $19.00 | $175.16K | 87,950 |
| John C.M. Farquhar Chief Executive Officer, Director | May 11, 2026 | Sale(10b5-1 plan) | −22,562 | $29.12 | $657.01K | 519,397 |
| John C.M. Farquhar Chief Executive Officer, Director | May 7, 2026 | Tax withholding | −1,904 | $29.98 | $57.08K | 541,959 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
15.86%
6M shares short
Days to cover
3.5
At 2M shares a day
Change since last report
-22.4%
From 7M shares
Short volume, 20 days
47.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Heartflow's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,000 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John C.M. Farquhar Officer, Director | Nov 10, 2026 | 38,900 | $2.17M | Nov 10, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Nov 9, 2026 | 3,587 | $190.65K | Nov 9, 2026 | Restricted Stock Vesting |
| Campbell Rogers Officer | Oct 22, 2026 | 23,933 | $1.32M | Oct 22, 2026 | Stock Option Exercise |
| Campbell Rogers Member of immediate family of any of the foregoing | Oct 22, 2026 | 5,654 | $311.03K | Oct 22, 2026 | Stock Option Exercise |
| John C.M. Farquhar Officer, Director | Oct 13, 2026 | 38,900 | $1.93M | Oct 12, 2026 | Stock Option Exercise |
| Campbell Rogers Officer | Sep 18, 2026 | 19,682 | $987.05K | Sep 18, 2026 | Stock Option Exercise |
| Campbell Rogers Member of immediate family of any of the foregoing | Sep 18, 2026 | 5,653 | $283.50K | Sep 18, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 18, 2026 | 16,766 | $850.93K | Sep 18, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 17, 2026 | 7,579 | $379.82K | Sep 17, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 15, 2026 | 668 | $33.41K | Sep 15, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 14, 2026 | 4,593 | $230.74K | Sep 14, 2026 | Stock Option Exercise |
| John C.M. Farquhar Officer, Director | Sep 11, 2026 | 3,890 | $194.50K | Sep 11, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 11, 2026 | 29,714 | $1.49M | Sep 11, 2026 | Stock Option Exercise |
| John C.M. Farquhar Officer, Director | Sep 10, 2026 | 35,010 | $1.63M | Sep 10, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 8, 2026 | 6,640 | $332.21K | Sep 8, 2026 | Stock Option Exercise |
See a number that looks wrong?